Antibody-drug conjugate highly effective in preventing recurrence in early stage HER2+ breast cancer, trial finds

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found. In a clinical trial involving 512 patients with the earliest stage of breast cancer that tested positive for the HER2 protein, 97% of those treated with trastuzumab emtansine (T-DM1) after surgery were alive and free of invasive cancer five years after treatment. The results, published in the Journal of Clinical Oncology, Read More

Related posts:

  1. Researchers complete first trial of Black patients with early-stage breast cancer
  2. Researchers discover promising approach to prevent recurrence of breast cancer
  3. New predictors of metastasis in patients with early-stage pancreatic cancer
  4. Entering the golden age for antibody-drug conjugates in gynecologic cancer
  5. Trained peers are as effective as clinical social workers in reducing opioid overdose, new trial finds
  6. Measuring tumor infiltrating lymphocytes predicts long term outcomes for type of early breast cancer
  7. Blood cancer drug could make radiotherapy on brain tumors more effective
  8. Immunotherapy before surgery very successful in treating colorectal cancer, trial finds

Leave a Reply

Your email address will not be published. Required fields are marked *